Page 330 - Demo

Addendum328List of publicationsThis thesisMüller, A. R., Brands, M. M., van de Ven, P. M., Roes, K. C., Cornel, M. C., van Karnebeek, C. D., ... & van Eeghen, A. M. (2021). Systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders: the power of 1. Neurology, 96(11), 529-540. DOI: 10.1212/WNL.0000000000011597Müller, A. R., Zinkstok, J. R., Rommelse, N. N. J., van de Ven, P. M., Roes, K. C. B., Wijburg, F. A., ... & van Eeghen, A. M. (2021). Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith–Magenis syndrome: protocol for a series of N-of-1 trials. Orphanet Journal of Rare Diseases, 16(1), 1-9. DOI: 10.1186/s13023-021-02003-zMüller, A. R., Luijten, M. A. J., Haverman, L., de Ranitz-Greven, W. L., Janssens, P., Rietman, A. B., … & van Eeghen A.M. (2023). Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROM. BMC Med, 21, 298. DOI: 10.1186/s12916-023-03012-4.Müller, A. R., den Hollander, B., van de Ven, P. M., Roes, K. C. B., Geertjens, L., Bruining, H., … & van Eeghen, A. M. (2023). Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with Tuberous Sclerosis Complex, mucopolysaccharidosis type III and Fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials. Submitted.Müller, A. R., van Silfhout, N. Y., den Hollander, B., Kampman, H. C., Bakkum, L., Brands, M. M. M. G., … & van Eeghen, A. M. (2023). Navigating the outcome maze: A scoping review of outcomes and instruments in clinical trials in genetic neurodevelopmental disorders and intellectual disability. Submitted.Bakkum, L., Paalman, C., Müller, A. R., van Eeghen, A. M., & Schuengel, C. (2023). Accessibility and Feasibility of Experience Sampling Methods for Mental Health Research with People with Intellectual Disability: Scoping of Research and Stakeholder Views. Submitted.Annelieke Muller sHL.indd 328 14-11-2023 09:08